Colin Walsh insider trades: Attovia Therapeutics (ATTO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Colin reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | ATTO | ↑ Buy | 585,000 | $17.58 | $10.3M | Indirect | Aug 28, 2026 (22d) |
| Aug 6, 2026 | ATTO | ↑ Buy | 585,000 | $17.58 | $10.3M | Indirect | Aug 13, 2026 (7d) |
| Aug 5, 2026 | ATTO | ↓ Sell | 105,807 | $21.28 | $2.3M | Indirect | Aug 28, 2026 (23d) |
| Aug 5, 2026 | ATTO | ↓ Sell | 105,807 | $21.28 | $2.3M | Indirect | Aug 13, 2026 (8d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ATTO insiders
Open-market trades in the last 12 months
About Colin Walsh's insider trades
Colin Walsh is a director at Attovia Therapeutics (ATTO). Since Aug 5, 2026, Colin has reported 2 open-market purchases worth $20.6M and 2 sales worth $4.5M on SEC Form 4. In the last 12 months: 2 buys ($20.6M) and 2 sales ($4.5M).
Their filings also include grants and awards (3 filings), conversions (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ATTO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.